Bayer Drug Patent Portfolio
Bayer owns 33 orange book drugs protected by 116 US patents with Claritin having the least patent protection, holding only 1 patent. And Vitrakvi with maximum patent protection, holding 20 patents. Given below is the list of Bayer's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12329742 | Pharmaceutical composition of darolutamide | 14 May, 2042 | Active |
| US10774091 | 13 Mar, 2039 | Active | |
| US11787820 | 13 Mar, 2039 | Active | |
| US12264164 | 13 Mar, 2039 | Active | |
| US11168058 | Manufacture of a crystalline pharmaceutical product | 27 Feb, 2038 | Active |
| US11337967 | Methods of treatment | 16 May, 2037 | Active |
| US11974998 | Methods of treatment | 16 May, 2037 | Active |
| US10045991 | Methods of treating pediatric cancers | 04 Apr, 2037 | Active |
| US10137127 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | 04 Apr, 2037 | Active |
| US10668072 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | 04 Apr, 2037 | Active |
| US11191766 | Methods of treating pediatric cancers | 04 Apr, 2037 | Active |
| US11484535 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | 04 Apr, 2037 | Active |
| US10799505 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 15 Aug, 2036 | Active |
| US10195205 | 18 May, 2036 | Active | |
| US10010530 | Carboxamide derivative and its diastereomers in stable crystalline form | 28 Jan, 2036 | Active |
| US10383853 | Carboxamide derivative and its diastereomers in stable crystalline form | 28 Jan, 2036 | Active |
| US10835515 | Carboxamide derivative and its diastereomers in stable crystalline form | 28 Jan, 2036 | Active |
| US10428063 | 25 Jan, 2036 | Active | |
| US10172861 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 16 Nov, 2035 | Active |
| US10285993 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 16 Nov, 2035 | Active |
| US10813936 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 16 Nov, 2035 | Active |
| US9782414 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 16 Nov, 2035 | Active |
| USRE49826 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient | 29 Jul, 2035 | Active |
| US10662188 | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate | 18 Feb, 2034 | Active |
| US11203593 | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate | 18 Feb, 2034 | Active |
| US8975254 | Androgen receptor modulating compounds | 25 Mar, 2033 | Active |
| US9957232 | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate | 09 Jul, 2032 | Active |
| US10383876 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts | 29 Mar, 2032 | Active |
| US9636344 | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts | 29 Mar, 2032 | Active |
| US8906890 | Very low-dosed solid oral dosage forms for HRT | 22 Oct, 2031 | Active |
| US9458107 | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate | 08 Apr, 2031 | Active |
| US10987244 | Inserter | 01 Apr, 2031 | Active |
| US9668912 | Inserter | 01 Apr, 2031 | Active |
| US8637553 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | 16 Feb, 2031 | Active |
| US10711013 | Androgen receptor modulating compounds | 27 Oct, 2030 | Active |
| US11046713 | Androgen receptor modulating compounds | 27 Oct, 2030 | Active |
| US9657003 | Androgen receptor modulating compounds | 27 Oct, 2030 | Active |
| US11617751 | Pharmaceutical composition containing a tetrahydrofolic acid | 17 Jul, 2030 | Active |
| US8680124 | Treatment of cancers with acquired resistance to kit inhibitors | 02 Jun, 2030 | Active |
| US8617597 | Pharmaceutical composition containing a tetrahydrofolic acid | 08 Feb, 2030 | Active |
| US8513263 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | 23 Dec, 2029 | Active |
| US8466283 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | 22 Oct, 2029 | Active |
| USRE46856 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | 22 Oct, 2029 | Active |
| US10005783 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | 21 Oct, 2029 | Active |
| US10047097 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | 21 Oct, 2029 | Active |
| US10774085 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | 21 Oct, 2029 | Active |
| US8865698 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | 21 Oct, 2029 | Active |
| US9127013 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | 21 Oct, 2029 | Active |
| US9447104 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | 21 Oct, 2029 | Active |
| US9676783 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | 21 Oct, 2029 | Active |
| US10561524 | Inserter | 16 Sep, 2029 | Active |
| US9615965 | Inserter | 16 Sep, 2029 | Active |
| US11850182 | Inserter | 14 Sep, 2029 | Active |
| US8436180 | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | 12 Apr, 2029 | Active |
| US8613950 | Pharmaceutical forms with improved pharmacokinetic properties | 23 Dec, 2028 | Active |
| US9737488 | Pharmaceutical composition for the treatment of cancer | 10 Sep, 2028 | Active |
| US8071073 | Compositions comprising azelastine and methods of use thereof | 04 Jun, 2028 | Active |
| US8153616 | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same | 30 Jan, 2028 | Active |
| US8877933 | Thermodynamically stable form of a tosylate salt | 24 Dec, 2027 | Active |
| US8273876 | Medicaments containing vardenafil hydrochloride trihydrate | 23 Jul, 2027 | Active |
| US8791127 | Mucosal bioadhesive slow release carrier for delivering active principles | 23 Mar, 2027 | Active |
| US11628088 | Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection | 07 Feb, 2027 | Active |
| US7173037 | Carbamate-substituted pyrazolopyridines | 04 Dec, 2026 | Active |
| US7683056 | 15 Sep, 2026 | Active | |
| US8071577 | Multi-phase contraceptive preparation based on a natural estrogen | 13 May, 2026 | Active |
| US8518919 | Compositions comprising azelastine and methods of use thereof | 22 Nov, 2025 | Expired |
| US9919050 | Compositions comprising azelastine | 22 Nov, 2025 | Expired |
| US7511041 | Fused azole-pyrimidine derivatives | 13 May, 2024 | Expired |
| US7252839 | Delivery system and a manufacturing process of a delivery system | 13 Nov, 2023 | Expired |
| US8841446 | Medicaments containing vardenafil hydrochloride trihydrate | 03 Jul, 2023 | Expired |
| US8618141 | Aryl ureas with angiogenesis inhibiting activity | 11 Feb, 2023 | Expired |
| US7709022 | Sustained-release preparations of quinolone antibiotics and method for preparation thereof | 23 Dec, 2021 | Expired |
| US8187632 | Sustained-release preparations of quinolone antibiotics | 23 Dec, 2021 | Expired |
| US6958326 | Cyclodextrin-drospirenone inclusion complexes | 20 Dec, 2021 | Expired |
| US7163931 | Compositions of estrogen-cyclodextrin complexes | 20 Dec, 2021 | Expired |
| US6039931 | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production | 13 Nov, 2021 | Expired |
| US5980864 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them | 09 Nov, 2021 | Expired |
| US7709022 | Sustained-release preparations of quinolone antibiotics and method for preparation thereof | 23 Jun, 2021 | Expired |
| US8187632 | Sustained-release preparations of quinolone antibiotics | 23 Jun, 2021 | Expired |
| US6787531 | Pharmaceutical composition for use as a contraceptive | 31 Aug, 2020 | Expired |
| US6548079 | Moxifloxacin formulation containing common salt | 25 Jul, 2020 | Expired |
| US6441168 | Stable crystalline salts of 5-methyltetrahydrofolic acid | 17 Apr, 2020 | Expired |
| US7235576 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | 12 Jan, 2020 | Expired |
| US7351834 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | 12 Jan, 2020 | Expired |
| US7897623 | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors | 12 Jan, 2020 | Expired |
| US8124630 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | 12 Jan, 2020 | Expired |
| US8841330 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | 12 Jan, 2020 | Expired |
| US6635234 | Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning | 03 Jan, 2020 | Expired |
| US6610327 | Pharmaceutical moxifloxacin preparation | 29 Oct, 2019 | Expired |
| US6743798 | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings | 16 Jul, 2019 | Expired |
| US6362178 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | 31 Oct, 2018 | Expired |
| US7696206 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | 31 Oct, 2018 | Expired |
| US6132758 | Stabilized antihistamine syrup | 01 Jun, 2018 | Expired |
| US6987101 | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder | 22 Dec, 2017 | Expired |
| US5891868 | Methods for treating postmenopausal women using ultra-low doses of estrogen | 21 Nov, 2017 | Expired |
| US6692763 | Methods for treating postmenopausal women using ultra-low doses of estrogen | 21 Nov, 2017 | Expired |
| US6933395 | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY | 11 Aug, 2017 | Expired |
| US5849752 | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification | 05 Dec, 2016 | Expired |
| US6133251 | Combination compound for contraception based on natural estrogen | 25 Oct, 2016 | Expired |
| US6884793 | Combination preparation for contraception based on natural estrogens | 25 Oct, 2016 | Expired |
| US5785053 | Inserter for the positioning of an intrauterine device | 05 Dec, 2015 | Expired |
| US5798092 | Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production | 25 Aug, 2015 | Expired |
| US5798338 | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol | 10 Jul, 2015 | Expired |
| US5695784 | Flavor-masked pharmaceutical compositions | 09 Jun, 2015 | Expired |
| US5695784 | Flavor-masked pharmaceutical compositions | 09 Dec, 2014 | Expired |
| US5676968 | Transdermal therapeutic systems with crystallization inhibitors | 14 Oct, 2014 | Expired |
| USRE37564 | Composition for contraception | 30 Jun, 2014 | Expired |
| USRE37838 | Composition for contraception | 30 Jun, 2014 | Expired |
| USRE38253 | Composition for contraception | 30 Jun, 2014 | Expired |
| USRE43916 | Composition for contraception | 30 Jun, 2014 | Expired |
| US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives | 04 Mar, 2014 | Expired |
| US5569652 | Dihydrospirorenone as an antiandrogen | 29 Oct, 2013 | Expired |
| US6136347 | Flavor-masked pharmaceutical compositions | 06 Jul, 2013 | Expired |
| US5314697 | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine | 23 Apr, 2013 | Expired |
| US6136347 | Flavor-masked pharmaceutical compositions | 06 Jan, 2013 | Expired |
| US5314697 | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine | 23 Oct, 2012 | Expired |
Latest Legal Activities on Bayer's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bayer.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 01 Jul, 2024 | US8187632 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Apr, 2024 | US10813936 |
|
Expire Patent
Critical
| 01 Apr, 2024 | US8124630 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 27 Mar, 2024 | US10799505 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Mar, 2024 | US9458107 |
| Letter from FDA or Dept of Agriculture re PTE application | 18 Mar, 2024 | US7511041 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Mar, 2024 | US8273876 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Mar, 2024 | US9447104 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Feb, 2024 | US10774085 |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Jan, 2024 | US8187632 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 04 Jan, 2024 | US10711013 |
| Recordation of Patent eGrant | 26 Dec, 2023 | US11850182 |
| Mail Patent eGrant Notification | 26 Dec, 2023 | US11850182 |
|
Email Notification
Critical
| 26 Dec, 2023 | US11850182 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 26 Dec, 2023 | US11850182 |
Bayer's Drug Patent Litigations
Bayer's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 17, 2005, against patent number US8124630. The petitioner , challenged the validity of this patent, with Bernd Riedl et al as the respondent. Click below to track the latest information on how companies are challenging Bayer's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9957232 | November, 2015 |
Decision
(14 Feb, 2017)
| Alfons Grunenberg et al | |
| US8637553 | July, 2016 |
Institution Denied
(08 Feb, 2017)
| Bayer HealthCare LLC | Fustibal LLC |
| US8637553 | July, 2016 |
Terminated-Denied
(08 Feb, 2017)
| Bayer HealthCare LLC | Fustibal LLC |
| US8071073 | May, 2014 |
Institution Denied
(29 Jul, 2014)
| Meda Pharmaceuticals Inc. | Impax Laboratories, Inc. |
| US8071073 | May, 2014 |
Terminated-Denied
(29 Jul, 2014)
| Meda Pharmaceuticals Inc. | Impax Laboratories, Inc. |
| US8187632 | June, 2010 |
Decision
(08 Nov, 2011)
| Venkata-Rangarao Kanikanti et al | |
| US8124630 | June, 2005 |
Decision
(27 Dec, 2005)
| Bernd Riedl et al | |
Bayer Drug Patents' Oppositions Filed in EPO
Bayer drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 03, 2008, by N.V. Organon. This opposition was filed on patent number EP03797325A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP16704029A | Feb, 2023 | Hamm&Wittkopp Patentanwälte PartmbB | Granted and Under Opposition |
| EP10183693A | Jul, 2017 | Accord Healthcare Ltd | Opposition rejected |
| EP10183693A | Jul, 2017 | Teva Pharmaceutical Industries Ltd | Opposition rejected |
| EP10183693A | Jul, 2017 | Zentiva k.s. | Opposition rejected |
| EP03707846A | Apr, 2014 | Accord Healthcare Ltd | Revoked |
| EP03707846A | Apr, 2014 | Hetero Drugs Ltd. | Revoked |
| EP07818583A | Mar, 2014 | Fresenius Kabi Deutschland GmbH | Opposition rejected |
| EP09736608A | Feb, 2014 | Actavis Group PTC ehf | Patent maintained as amended |
| EP09736244A | Sep, 2013 | Actavis Group PTC EHF | Patent maintained as amended |
| EP05797740A | Mar, 2013 | Biofer S.p.A. | Revoked |
| EP05797740A | Mar, 2013 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP06706994A | Jan, 2013 | Accord Healthcare Ltd | Opposition rejected |
| EP06706994A | Jan, 2013 | Generics [UK] Limited | Opposition rejected |
| EP03763695A | Sep, 2012 | Accord Healthcare Ltd | Revoked |
| EP03763695A | Sep, 2012 | Zentiva k.s. | Revoked |
| EP06707141A | Jun, 2011 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP06707141A | Jun, 2011 | Altmann, Andreas | Revoked |
| EP05730867A | Apr, 2011 | Lupin Limited | Patent maintained as amended |
| EP05730867A | Apr, 2011 | Laboratorios Léon Farma, S.A. | Patent maintained as amended |
| EP05022324A | Nov, 2009 | Sandoz International GmbH | Revoked |
| EP03797325A | Dec, 2008 | N.V. Organon | Patent maintained as amended |
Bayer's Family Patents
Clinical Trials
Recent Clinical Trials by Bayer:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions | Bayer | Janssen Research & Development, LLC |
COMPLETED
(Jun, 2015)
| PHASE1 |
Bayer Drug List
Given below is the complete list of Bayer's drugs and the patents protecting them.
1. Adempas
Adempas is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10662188 | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
18 Feb, 2034
(8 years from now)
| Active |
| US11203593 | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
18 Feb, 2034
(8 years from now)
| Active |
| US7173037 | Carbamate-substituted pyrazolopyridines |
04 Dec, 2026
(10 months from now)
| Active |
| US6743798 | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
16 Jul, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adempas's drug page
2. Aliqopa
Aliqopa is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10383876 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
29 Mar, 2032
(6 years from now)
| Active |
| US9636344 | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts |
29 Mar, 2032
(6 years from now)
| Active |
| US8466283 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
22 Oct, 2029
(3 years from now)
| Active |
| USRE46856 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
22 Oct, 2029
(3 years from now)
| Active |
| US7511041 | Fused azole-pyrimidine derivatives |
13 May, 2024
(1 year, 7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aliqopa's drug page
3. Angeliq
Angeliq is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8906890 | Very low-dosed solid oral dosage forms for HRT |
22 Oct, 2031
(5 years from now)
| Active |
| US6933395 | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
11 Aug, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Angeliq's drug page
4. Astepro Allergy
Astepro Allergy is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8071073 | Compositions comprising azelastine and methods of use thereof |
04 Jun, 2028
(2 years from now)
| Active |
| US8518919 | Compositions comprising azelastine and methods of use thereof |
22 Nov, 2025
(a month ago)
| Expired |
| US9919050 | Compositions comprising azelastine |
22 Nov, 2025
(a month ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Astepro Allergy's drug page
5. Avelox
Avelox is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6610327 | Pharmaceutical moxifloxacin preparation |
29 Oct, 2019
(6 years ago)
| Expired |
| US5849752 | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
05 Dec, 2016
(9 years ago)
| Expired |
| US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
04 Mar, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avelox's drug page
Explore Our Curated Drug Screens
6. Avelox In Sodium Chloride 0.8% In Plastic Container
Avelox In Sodium Chloride 0.8% In Plastic Container is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6548079 | Moxifloxacin formulation containing common salt |
25 Jul, 2020
(5 years ago)
| Expired |
| US5849752 | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
05 Dec, 2016
(9 years ago)
| Expired |
| US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
04 Mar, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avelox In Sodium Chloride 0.8% In Plastic Container's drug page
7. Beyaz
Beyaz is protected by 10 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11617751 | Pharmaceutical composition containing a tetrahydrofolic acid |
17 Jul, 2030
(4 years from now)
| Active |
| US8617597 | Pharmaceutical composition containing a tetrahydrofolic acid |
08 Feb, 2030
(4 years from now)
| Active |
| US7163931 | Compositions of estrogen-cyclodextrin complexes |
03 Mar, 2022
(3 years ago)
| Expired |
| US6958326 | Cyclodextrin-drospirenone inclusion complexes |
30 Dec, 2021
(4 years ago)
| Expired |
| US6441168 | Stable crystalline salts of 5-methyltetrahydrofolic acid |
17 Apr, 2020
(5 years ago)
| Expired |
| US5798338 | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
10 Jul, 2015
(10 years ago)
| Expired |
| USRE37564 | Composition for contraception |
30 Jun, 2014
(11 years ago)
| Expired |
| USRE37838 | Composition for contraception |
30 Jun, 2014
(11 years ago)
| Expired |
| USRE38253 | Composition for contraception |
30 Jun, 2014
(11 years ago)
| Expired |
| USRE43916 | Composition for contraception |
30 Jun, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Beyaz's drug page
8. Children's Astepro Allergy
Children's Astepro Allergy is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8071073 | Compositions comprising azelastine and methods of use thereof |
04 Jun, 2028
(2 years from now)
| Active |
| US8518919 | Compositions comprising azelastine and methods of use thereof |
22 Nov, 2025
(a month ago)
| Expired |
| US9919050 | Compositions comprising azelastine |
22 Nov, 2025
(a month ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Children's Astepro Allergy's drug page
9. Cipro
Cipro is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5695784
(Pediatric)
| Flavor-masked pharmaceutical compositions |
09 Jun, 2015
(10 years ago)
| Expired |
| US5695784 | Flavor-masked pharmaceutical compositions |
09 Dec, 2014
(11 years ago)
| Expired |
| US6136347
(Pediatric)
| Flavor-masked pharmaceutical compositions |
06 Jul, 2013
(12 years ago)
| Expired |
| US6136347 | Flavor-masked pharmaceutical compositions |
06 Jan, 2013
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cipro's drug page
10. Cipro Xr
Cipro Xr is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7709022
(Pediatric)
| Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
23 Dec, 2021
(4 years ago)
| Expired |
| US8187632
(Pediatric)
| Sustained-release preparations of quinolone antibiotics |
23 Dec, 2021
(4 years ago)
| Expired |
| US7709022 | Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
23 Jun, 2021
(4 years ago)
| Expired |
| US8187632 | Sustained-release preparations of quinolone antibiotics |
23 Jun, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cipro Xr's drug page
11. Claritin
Claritin is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6132758 | Stabilized antihistamine syrup |
01 Jun, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Claritin's drug page
12. Claritin-d 24 Hour
Claritin-d 24 Hour is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5314697
(Pediatric)
| Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
23 Apr, 2013
(12 years ago)
| Expired |
| US5314697 | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
23 Oct, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Claritin-d 24 Hour's drug page
13. Climara Pro
Climara Pro is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5676968 | Transdermal therapeutic systems with crystallization inhibitors |
14 Oct, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Climara Pro's drug page
14. Eovist
Eovist is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6039931 | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production |
13 Nov, 2021
(4 years ago)
| Expired |
| US5798092 | Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production |
25 Aug, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eovist's drug page
15. Gadavist
Gadavist is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5980864 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
09 Nov, 2021
(4 years ago)
| Expired |
| US5980864 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
09 Nov, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gadavist's drug page
16. Hyrnuo
Hyrnuo is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10428063 |
25 Jan, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hyrnuo's drug page
17. Kerendia
Kerendia is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE49826 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
29 Jul, 2035
(9 years from now)
| Active |
| US8436180 | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
12 Apr, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kerendia's drug page
18. Kyleena
Kyleena is protected by 7 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10987244 | Inserter |
01 Apr, 2031
(5 years from now)
| Active |
| US9668912 | Inserter |
01 Apr, 2031
(5 years from now)
| Active |
| US10561524 | Inserter |
16 Sep, 2029
(3 years from now)
| Active |
| US9615965 | Inserter |
16 Sep, 2029
(3 years from now)
| Active |
| US11850182 | Inserter |
14 Sep, 2029
(3 years from now)
| Active |
| US11628088 | Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection |
07 Feb, 2027
(1 year, 30 days from now)
| Active |
| US7252839 | Delivery system and a manufacturing process of a delivery system |
13 Nov, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kyleena's drug page
19. Levitra
Levitra is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8273876 | Medicaments containing vardenafil hydrochloride trihydrate |
23 Jul, 2027
(1 year, 6 months from now)
| Active |
| US8841446 | Medicaments containing vardenafil hydrochloride trihydrate |
03 Jul, 2023
(2 years ago)
| Expired |
| US6362178 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
31 Oct, 2018
(7 years ago)
| Expired |
| US7696206 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
31 Oct, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levitra's drug page
20. Lynkuet
Lynkuet is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10774091 |
13 Mar, 2039
(13 years from now)
| Active | |
| US11787820 |
13 Mar, 2039
(13 years from now)
| Active | |
| US12264164 |
13 Mar, 2039
(13 years from now)
| Active | |
| US10195205 |
18 May, 2036
(10 years from now)
| Active | |
| US7683056 |
15 Sep, 2026
(8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lynkuet's drug page
21. Menostar
Menostar is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5891868 | Methods for treating postmenopausal women using ultra-low doses of estrogen |
21 Nov, 2017
(8 years ago)
| Expired |
| US6692763 | Methods for treating postmenopausal women using ultra-low doses of estrogen |
21 Nov, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Menostar's drug page
22. Mirena
Mirena is protected by 6 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10987244 | Inserter |
01 Apr, 2031
(5 years from now)
| Active |
| US9668912 | Inserter |
01 Apr, 2031
(5 years from now)
| Active |
| US10561524 | Inserter |
16 Sep, 2029
(3 years from now)
| Active |
| US9615965 | Inserter |
16 Sep, 2029
(3 years from now)
| Active |
| US11850182 | Inserter |
14 Sep, 2029
(3 years from now)
| Active |
| US5785053 | Inserter for the positioning of an intrauterine device |
05 Dec, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mirena's drug page
23. Natazia
Natazia is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8153616 | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
30 Jan, 2028
(2 years from now)
| Active |
| US8071577 | Multi-phase contraceptive preparation based on a natural estrogen |
13 May, 2026
(4 months from now)
| Active |
| US6133251 | Combination compound for contraception based on natural estrogen |
25 Oct, 2016
(9 years ago)
| Expired |
| US6884793 | Combination preparation for contraception based on natural estrogens |
25 Oct, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Natazia's drug page
24. Nexavar
Nexavar is protected by 8 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9737488 | Pharmaceutical composition for the treatment of cancer |
10 Sep, 2028
(2 years from now)
| Active |
| US8877933 | Thermodynamically stable form of a tosylate salt |
24 Dec, 2027
(1 year, 11 months from now)
| Active |
| US8618141 | Aryl ureas with angiogenesis inhibiting activity |
11 Feb, 2023
(2 years ago)
| Expired |
| US7235576 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
12 Jan, 2020
(5 years ago)
| Expired |
| US7351834 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
12 Jan, 2020
(5 years ago)
| Expired |
| US7897623 | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
12 Jan, 2020
(5 years ago)
| Expired |
| US8124630 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
12 Jan, 2020
(5 years ago)
| Expired |
| US8841330 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
12 Jan, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexavar's drug page
25. Nubeqa
Nubeqa is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12329742 | Pharmaceutical composition of darolutamide |
14 May, 2042
(16 years from now)
| Active |
| US11168058 | Manufacture of a crystalline pharmaceutical product |
27 Feb, 2038
(12 years from now)
| Active |
| US10010530 | Carboxamide derivative and its diastereomers in stable crystalline form |
28 Jan, 2036
(10 years from now)
| Active |
| US10383853 | Carboxamide derivative and its diastereomers in stable crystalline form |
28 Jan, 2036
(10 years from now)
| Active |
| US10835515 | Carboxamide derivative and its diastereomers in stable crystalline form |
28 Jan, 2036
(10 years from now)
| Active |
| US8975254 | Androgen receptor modulating compounds |
25 Mar, 2033
(7 years from now)
| Active |
| US10711013 | Androgen receptor modulating compounds |
27 Oct, 2030
(4 years from now)
| Active |
| US11046713 | Androgen receptor modulating compounds |
27 Oct, 2030
(4 years from now)
| Active |
| US9657003 | Androgen receptor modulating compounds |
27 Oct, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nubeqa's drug page
26. Safyral
Safyral is protected by 6 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11617751 | Pharmaceutical composition containing a tetrahydrofolic acid |
17 Jul, 2030
(4 years from now)
| Active |
| US8617597 | Pharmaceutical composition containing a tetrahydrofolic acid |
08 Feb, 2030
(4 years from now)
| Active |
| US7163931 | Compositions of estrogen-cyclodextrin complexes |
03 Mar, 2022
(3 years ago)
| Expired |
| US6958326 | Cyclodextrin-drospirenone inclusion complexes |
20 Dec, 2021
(4 years ago)
| Expired |
| US6441168 | Stable crystalline salts of 5-methyltetrahydrofolic acid |
17 Apr, 2020
(5 years ago)
| Expired |
| US5798338 | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
10 Jul, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Safyral's drug page
27. Skyla
Skyla is protected by 8 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10987244 | Inserter |
01 Apr, 2031
(5 years from now)
| Active |
| US9668912 | Inserter |
01 Apr, 2031
(5 years from now)
| Active |
| US10561524 | Inserter |
16 Sep, 2029
(3 years from now)
| Active |
| US9615965 | Inserter |
16 Sep, 2029
(3 years from now)
| Active |
| US11850182 | Inserter |
14 Sep, 2029
(3 years from now)
| Active |
| US11628088 | Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection |
07 Feb, 2027
(1 year, 30 days from now)
| Active |
| US7252839 | Delivery system and a manufacturing process of a delivery system |
13 Nov, 2023
(2 years ago)
| Expired |
| US5785053 | Inserter for the positioning of an intrauterine device |
05 Dec, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Skyla's drug page
28. Staxyn
Staxyn is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8613950 | Pharmaceutical forms with improved pharmacokinetic properties |
23 Dec, 2028
(2 years from now)
| Active |
| US6362178 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
31 Oct, 2018
(7 years ago)
| Expired |
| US7696206 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
31 Oct, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Staxyn's drug page
29. Stivarga
Stivarga is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9957232 | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
09 Jul, 2032
(6 years from now)
| Active |
| US9458107 | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate |
08 Apr, 2031
(5 years from now)
| Active |
| US8637553 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
16 Feb, 2031
(5 years from now)
| Active |
| US8680124 | Treatment of cancers with acquired resistance to kit inhibitors |
02 Jun, 2030
(4 years from now)
| Active |
| US7351834 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
12 Jan, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Stivarga's drug page
30. Vitrakvi
Vitrakvi is protected by 20 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11337967 | Methods of treatment |
16 May, 2037
(11 years from now)
| Active |
| US11974998 | Methods of treatment |
16 May, 2037
(11 years from now)
| Active |
| US10045991 | Methods of treating pediatric cancers |
04 Apr, 2037
(11 years from now)
| Active |
| US10137127 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
04 Apr, 2037
(11 years from now)
| Active |
| US10668072 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
04 Apr, 2037
(11 years from now)
| Active |
| US11191766 | Methods of treating pediatric cancers |
04 Apr, 2037
(11 years from now)
| Active |
| US11484535 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
04 Apr, 2037
(11 years from now)
| Active |
| US10799505 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
15 Aug, 2036
(10 years from now)
| Active |
| US10172861 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
16 Nov, 2035
(9 years from now)
| Active |
| US10285993 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
16 Nov, 2035
(9 years from now)
| Active |
| US10813936 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
16 Nov, 2035
(9 years from now)
| Active |
| US9782414 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
16 Nov, 2035
(9 years from now)
| Active |
| US8513263 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
23 Dec, 2029
(3 years from now)
| Active |
| US10005783 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
21 Oct, 2029
(3 years from now)
| Active |
| US10047097 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
21 Oct, 2029
(3 years from now)
| Active |
| US10774085 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
21 Oct, 2029
(3 years from now)
| Active |
| US8865698 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
21 Oct, 2029
(3 years from now)
| Active |
| US9127013 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
21 Oct, 2029
(3 years from now)
| Active |
| US9447104 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
21 Oct, 2029
(3 years from now)
| Active |
| US9676783 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
21 Oct, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vitrakvi's drug page
31. Xofigo
Xofigo is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8791127 | Mucosal bioadhesive slow release carrier for delivering active principles |
23 Mar, 2027
(1 year, 2 months from now)
| Active |
| US6635234 | Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning |
03 Jan, 2020
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xofigo's drug page
32. Yasmin
Yasmin is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6787531 | Pharmaceutical composition for use as a contraceptive |
31 Aug, 2020
(5 years ago)
| Expired |
| US6933395 | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
11 Aug, 2017
(8 years ago)
| Expired |
| US5569652 | Dihydrospirorenone as an antiandrogen |
29 Oct, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yasmin's drug page
33. Yaz
Yaz is protected by 11 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6958326 | Cyclodextrin-drospirenone inclusion complexes |
20 Dec, 2021
(4 years ago)
| Expired |
| US7163931 | Compositions of estrogen-cyclodextrin complexes |
20 Dec, 2021
(4 years ago)
| Expired |
| US6787531 | Pharmaceutical composition for use as a contraceptive |
31 Aug, 2020
(5 years ago)
| Expired |
| US6987101 | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
22 Dec, 2017
(8 years ago)
| Expired |
| US6933395 | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
11 Aug, 2017
(8 years ago)
| Expired |
| US5798338 | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
10 Jul, 2015
(10 years ago)
| Expired |
| USRE37564 | Composition for contraception |
30 Jun, 2014
(11 years ago)
| Expired |
| USRE37838 | Composition for contraception |
30 Jun, 2014
(11 years ago)
| Expired |
| USRE38253 | Composition for contraception |
30 Jun, 2014
(11 years ago)
| Expired |
| USRE43916 | Composition for contraception |
30 Jun, 2014
(11 years ago)
| Expired |
| US5569652 | Dihydrospirorenone as an antiandrogen |
29 Oct, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yaz's drug page